By Giulia Petroni
Novartis said that primary endpoint data from a Phase 3 trial showed that ribociclib drug treatment Kisqali significantly reduced the risk of cancer recurrence across a broad population of patients with early breast cancer.
The Swiss pharma giant on Friday said that ribociclib combined with endocrine therapy lowered the risk of cancer recurrence by 25.2% in patients compared to endocrine therapy alone, according to data from the Natalee trial.
The patients suffer from stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, according to the company.
"Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with early breast cancer, regardless of disease stage, menopausal or nodal status," Novartis said.
Novartis plans to submit Phase 3 data to regulatory authorities in the U.S. and Europe before end of year.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
06-02-23 0833ET